Reclassification of Software Automated Medical Devices
Navigate FDA, EMA, and global classification frameworks for software-driven medical devices — from AI-powered diagnostics to autonomous delivery systems.
Find upcoming live sessions and on-demand learning across quality, compliance, medical devices, technology, and life sciences.
See upcoming eventsDiscover sessions by topic, explore the curriculum, and continue to educraft.us to register.
Navigate FDA, EMA, and global classification frameworks for software-driven medical devices — from AI-powered diagnostics to autonomous delivery systems.
A comprehensive 2-day program covering the full supplier lifecycle — qualification, risk assessment, quality agreements, performance monitoring, and supplier exits.
Harness real-time digital quality signals and AI/ML analytics to boost compliance, detect deviations early, and align with FDA regulatory expectations.
Go beyond procedural compliance — learn how FDA and MHRA investigators evaluate laboratory oversight maturity and build defensible data integrity practices.
Move beyond paperwork compliance — build investigations that connect triggers to true root causes and CAPAs that hold up under FDA inspection scrutiny. 4 Modules.
Master instrument and method validation for liquid chromatography — meeting US EPA and FDA requirements to ensure every result is usable, reportable, and audit-ready.
Understand the irreducible error rates in AI systems and what FDA expects organizations to do about them before deploying AI in regulated environments.
Explore the Pharma 4.0 operating model and modern validation technologies to build inspection-ready data integrity programs that reduce cost and complexity.
A practical, compliance-aligned framework for using ChatGPT as a controlled writing tool in regulated industries — boosting productivity without compromising data integrity.
Understand what modern regulators actually evaluate in IQ, OQ, PQ, and PPQ activities — and how to produce defensible, risk-based validation evidence that goes beyond documentation volume.
Stay ahead of FDA's evolving AI expectations in GMP environments — before guidance is finalized and before your next inspection.
Understand how FDA enforcement actions on AI are reshaping compliance expectations and what your organization must do to stay inspection-ready.
Master a repeatable, closed-loop failure investigation methodology — using flow charts, the 5 Whys, and 7 powerful tools to resolve root problems and build CAPA that holds up under FDA inspection.
Understand where AI genuinely improves efficiency in CAPA workflows — and where it creates hidden regulatory risk in root cause analysis and investigation defensibility.
Move beyond document-centric compliance — learn how to structure device records as an interconnected system of relationships that holds up under FDA inspection scrutiny.
Navigate the practical regulatory, quality, and operational implications of FDA's modernized OTC monograph system and OMUFA II — from product lifecycle decisions to documentation requirements.
Learn how to interpret OOS results clearly, recognize investigation gaps, and align every decision with current FDA expectations for 2026.
A practical compliance session on 21 CFR Part 11, EU GMP Annex 11, ALCOA+ principles, electronic signatures, hybrid documentation systems, and inspection-readiness for digital records environments.
Learn practical strategies to reduce deviation backlogs without sacrificing investigation quality or regulatory defensibility — and build sustainable systems to prevent future accumulation.
Translate Annex 1 contamination control expectations into practical sterile manufacturing decisions — CCS design, environmental monitoring interpretation, intervention management, and sterility assurance rationale.
Move beyond checkbox validation — define measurable, risk-based acceptance criteria for AI-enabled GxP systems aligned with FDA, EMA, MHRA, GAMP®, and data integrity expectations.
Implement a risk-based review-by-exception strategy that cuts reviewer fatigue and speeds batch release while strengthening detection of data integrity, compliance, and cybersecurity risks.
Learn the vital connection between documentation, compliance, and training — and how to leverage SOPs to measure and improve training effectiveness, job performance, and quality outcomes.
Master the GMP release systems, chain-of-identity controls, and traceability frameworks required to protect patient safety and maintain regulatory compliance in advanced therapy manufacturing.
Configure and validate GxP compliant Excel applications step-by-step — audit trails, security features, and data verification — no macros required.
Examine the practical realities of AI-assisted PMS while maintaining defensible regulatory oversight — signal evaluation, MDR reporting, and the human judgment regulators will still require.
A configuration-centered approach to assessing product changes across connected technical documentation — identifying where design modifications affect risk, clinical conclusions, verification evidence, and the regulatory record before inconsistencies become embedded.
Examines the operational impact of ICH Q14 and Q2(R2) beyond the guidance language — method flexibility, analytical control strategies, post-validation changes, and the evidence needed to sustain method performance throughout the product lifecycle.
Treat traceability as an observable property of a trustworthy product configuration — maintaining configured information and its relationships so traceability is produced, not reconstructed, as products evolve under QMSR and ISO 13485:2016.
Practical guidance on CGMP production controls using SPC, Six Sigma, and statistical methods — control charts, sampling plan justification, verification and validation evidence, and trending of NCMRs, complaints, and CAPAs.
A practical two-day framework for applying CSV, CSA, GAMP® 5, and quality risk management to cloud, SaaS, configurable, and AI-enabled GxP systems — with the emphasis on inspection readiness and regulatory-defensible decisions.
A strategic, risk-based approach to validating Excel spreadsheets used in FDA-regulated activities — GAMP 5 categorization, SDLC validation, Part 11 compliance, and inspection readiness.
A technical deep-dive into post-approval nitrosamine reassessment triggers, ICH M7 purge justifications, NDSRI/CPCA classification, and control strategy selection across FDA, EMA, and global frameworks.
Recurring software validation deficiencies found in FDA warning letters and consent decrees — the organizational decisions behind them, and the remediation FDA ultimately expects.
Design and evaluate media fills that meaningfully challenge aseptic operations, address contamination risks, support operator qualification, and show the process remains appropriately controlled.
A risk-based approach to validating data transfers and system integrations — interface requirements, data mapping, transformation rules, error handling, reconciliation, monitoring, and end-to-end data integrity.
Put ML-specific risk guidance into practice — Product Hazard Analysis, FMEA and FTA for ML risks, risk controls and verification, and managing the risk file across the Total Product Life Cycle.
A risk-based approach to vendor assurance that goes beyond certificates and questionnaires — deciding which vendor evidence to leverage, which claims to challenge, and which controls to independently verify.
Evaluate post-clearance device changes consistently, determine when existing clearance remains supportable, and document the regulatory rationale behind decisions to submit — or not submit — a new 510(k).
Get precise clarity on what Part 11, Annex 11, and EU GDPR actually require — covering local and cloud environments, AI software validation, electronic signatures, and fill-in-the-blank templates.
Meet EU Annex 22 requirements while harnessing AI, ML, and LLMs with the critical human oversight needed for quality, compliance, and ROI in FDA-regulated environments.
Risk-based decisions on when to investigate deeper, escalate, or close — recognizing systemic signals across deviations, OOS, and complaints, and why RCA so often fails to hold on repeat.
Trace sterility failures through laboratory, manufacturing, environmental, and contamination-source evidence to a defensible root cause, affected-batch decision, and CAPA.
Control the period between an emerging FDA inspection concern and the written 483 response — triage evidence, separate correction from remediation, and make commitments you can support.
A practical, risk-based framework for managing continuous SaaS and AI change while maintaining compliance, validated state, and inspection readiness — without a validation backlog.
Distinguish RBQM from RBM, identify Critical to Quality factors, and establish a practical implementation approach aligned with ICH E8(R1) and ICH E6(R3).
Establish a clearer oversight strategy, align supplier arrangements with ICH-GCP E6(R3), and prepare documentation and contractual evidence that supports inspection readiness.
Distinguish among 510(k), De Novo, PMA, and IDE pathways and evaluate how classification, risk, clinical evidence, AI/ML features, and Q-Sub, Breakthrough, and STeP programs affect U.S. market authorization.
Demonstrate CAPA effectiveness when failures are too infrequent for recurrence-based verification — alternative measures, leading indicators, risk-based monitoring periods, and defensible closure.
Build meaningful human oversight of AI in GMP — defined decision authority, documented intervention, traceability, and lifecycle monitoring proportional to GMP risk.
Keep validated cleaning processes in a state of control as products, equipment, campaigns, and analytical methods change — and decide when revalidation is warranted.
Establish supplier oversight proportionate to quality risk, identify weaknesses in outsourced operations, and use supplier performance, audit findings, and change-control information to support ongoing regulatory compliance.
Explore packaging and labeling controls, reduce hidden errors, and adapt operational practices as AI and increased production reshape the pharmaceutical supply chain.
Establish AI/ML model credibility for regulatory decision-making by connecting context of use, model risk, data relevance, performance, uncertainty, and supporting evidence.
Maintain cybersecurity throughout the lifecycle of SaMD, SiMD, and AI-enabled devices, including vulnerability assessment, patches, security testing, change impact assessments, and reassessment of risk controls and regulatory evidence.
Explore how sterilization, environmental monitoring, aseptic operations, investigations, and risk management work together within an integrated Contamination Control Strategy under EU GMP Annex 1.
Develop the technical judgment needed to establish analytical procedure suitability, verify compendial methods, transfer procedures between laboratories, and manage specifications and atypical results using applicable FDA, USP, and ICH requirements.
This masterclass builds the capability to classify, investigate, and document OOS and OOT events with disciplined scientific reasoning, reducing exposure to inspection findings, product impact decisions, and recurring quality failures while strengthening internal control over laboratory and manufacturing investigations.
Use APR/PQR data to identify emerging changes in process and product performance, connect quality trends, and assess when findings call for investigation, CAPA, revalidation, or changes to existing controls.
Explore how to build a clinical trial budget, account for study design, outsourcing and new technologies, and monitor expenditure and scope changes throughout the study.
Try a different topic or explore all sessions.
Dates are shown as published by EduCraft. Check the session page and educraft.us for start times, timezone, pricing, and availability. Past dates do not imply recording availability.